OrganoClick (ORGC) Q4 2025 earnings summary

Executive summary

• Net sales for 2025 were SEK 106.2 million, a decrease of 16.5% year-over-year, with a particularly weak Q4 marked by a 14.3% decline in sales compared to the same quarter last year.

• Operating loss (EBIT) for the year was SEK -31.6 million, with an adjusted EBIT of SEK -22.6 million excluding SEK 9 million in restructuring costs and inventory write-downs.

• A SEK 20 million efficiency program was implemented to reduce costs, with most effects expected from 2026.

• No dividend is proposed for 2025.

Financial highlights

• Gross margin for 2025 was 14.0%, down from 25.0% in 2024.

• EBITDA for the year was SEK -12.9 million, compared to SEK 5.7 million in 2024.

• Earnings per share before and after dilution was SEK -0.36, compared to SEK -0.18 last year.

• Cash flow from operating activities was SEK -8.3 million for the year.

• Net debt/equity ratio increased to 430.1% from 172.9% year-over-year.

Outlook and guidance

• Cost reductions from the efficiency program are expected to improve earnings in 2026, with positive effects visible from Q1.

• Sales in some segments may be temporarily impacted in early 2026 due to the end of a private label agreement and production planning at a major customer.

• Management expects improved demand, especially for green chemical products, and aims for profitable green growth.